Results 231 to 240 of about 99,547,245 (298)

Low-Dose Interleukin-2 Enhances Activated Suppressor Regulatory T Cells and CTLA-4 and HLA-DR Expression in Chronic Chikungunya Arthritis. [PDF]

open access: yesPathogens
Tritsch SR   +27 more
europepmc   +1 more source

MLMP: A Methylation‐Associated lncRNA‐mRNA Prognostic Signature for Endometrial Carcinoma

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Endometrial carcinoma (EC) is one of the most common gynecological malignancies. Aberrant DNA methylation (DNAm) is an important epigenetic alteration involved in cancer progression. Long non‐coding RNAs (LncRNAs) play critical roles in gene regulation and pathological processes.
Hong Kou   +10 more
wiley   +1 more source

CTLA-4 and targeted immunotherapy-a key link in the systemic influence of periodontitis: a mini review. [PDF]

open access: yesFront Dent Med
Thanigaimalai A   +4 more
europepmc   +1 more source

Intratumoral CTLA‐4 Blockade: Decoupling Local Immune Remodeling From Systemic Toxicity

open access: yes
MedComm – Oncology, Volume 5, Issue 4, December 2026.
Luyan Chen   +4 more
wiley   +1 more source

Immune Checkpoint Inhibitor Rechallenge After Immune‐Related Adverse Events: A Systematic Review and Meta‐Analysis

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Restarting immune checkpoint inhibitors (ICIs) after an immune‐related adverse event (irAE) requires balancing toxicity against antitumor benefit. Prior reviews often mixed post‐irAE restart with retreatment after progression or combined cohorts with case reports. This systematic review evaluated cohort evidence on ICI restart after
Xinwei Chen   +6 more
wiley   +1 more source

Adjuvant Immunotherapy for Resected Head and Neck Mucosal Melanoma: A Retrospective Cohort Study

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Head and neck mucosal melanoma (HNMM) is a rare, aggressive malignancy with high recurrence rates and limited prospective data to guide postoperative management. While immune checkpoint inhibitors (ICI) have reshaped melanoma treatment, their survival impact in resected HNMM remains poorly defined.
Dary Phen   +9 more
wiley   +1 more source

CTLA-4 Antisense Oligonucleotide Contributes to Enhanced Immunogenicity of an Adjuvanted Recombinant <i>Sporothrix</i> spp. Enolase Antigen. [PDF]

open access: yesVaccines (Basel)
Momente GJ   +8 more
europepmc   +1 more source

Immune Checkpoint Inhibitor‐Induced Diabetic Ketoacidosis in a Patient With Pre‐Existing Type 2 Diabetes: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT Immune checkpoint inhibitors (ICIs) may cause rare life‐threatening ICI‐associated diabetes mellitus. We report a 60‐year‐old Chinese male with pre‐existing type 2 diabetes who developed toripalimab‐induced diabetic ketoacidosis after 3 treatment cycles. He also had toripalimab‐related hyperthyroidism.
Lingfen Zeng, Jieming Sun
wiley   +1 more source

Home - About - Disclaimer - Privacy